US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

Purdue Pharma L.P.

Track this case

Case overview

Case Number:

7:19-bk-23649

Court:

New York Southern

Nature of Suit:

Firms

Companies

Government Agencies

Sectors & Industries:

  1. June 16, 2025

    All 50 States Agree To Purdue Pharma's $7.4B Settlement

    Attorneys general from 55 U.S. states and territories on Monday backed Purdue Pharma's $7.4 billion deal to settle opioid injury claims against the company and the Sackler family, almost a year after the U.S. Supreme Court threw out Purdue's previous plan to end litigation over its role in the opioid epidemic.

  2. June 13, 2025

    What's Happening In Bankruptcy Court This Coming Week

    Vodka company Stoli Group and pharmaceutical giant Purdue are both headed to court to make the case for their bankruptcy plan disclosure statements, New Hampshire power plant operator Burgess BioPower will try to get its Chapter 11 plan confirmed, and trucking company Yellow Corp. is facing a bid to send it to liquidation.

  3. June 12, 2025

    McKinsey Says Purdue Ch. 11 Plan Endangers Sackler Claims

    McKinsey & Co. has asked a New York bankruptcy judge to reject the disclosure statement for Purdue Pharma's Chapter 11 plan, saying there is ambiguity on how the plan will deal with the consulting firm's possible claims against former owners in the Sackler family.

  4. June 06, 2025

    Purdue Seeks To Stretch Ch. 11 Injunction To November

    Purdue Pharma has asked a New York bankruptcy judge to extend a litigation injunction in its Chapter 11 until late November or after it secures confirmation of its bankruptcy plan, whichever is earlier, saying the stay is protecting dozens of settlements.

  5. May 22, 2025

    Purdue Eyes Fall Confirmation For New Chapter 11 Plan

    Attorneys for Purdue Pharma told a New York bankruptcy judge Thursday that the company aims to send its Chapter 11 plan to a vote over the summer with a fall confirmation hearing to conclude the nearly 6-year-old case.

  6. April 14, 2025

    Debt Deals On The Rise, Purdue Can Begin Claims Processing

    A Texas district court, not a bankruptcy court, will oversee the U.S. trustee's efforts to claw back millions in legal fees paid to Jackson Walker over an undisclosed relationship between an attorney and bankruptcy judge; out-of-court debt deals eclipsed Chapter 11s by a 4-to-1 ratio last year; and drug manufacturer Purdue Pharma can begin processing claims ahead of a Chapter 11 confirmation hearing. This is the week in bankruptcy.

  7. April 10, 2025

    Purdue Cleared To Start Ch. 11 Claims Processing Early

    A New York bankruptcy judge on Thursday approved Purdue Pharma's request to appoint claims administrators and begin processing the tens of thousands of claims against the drugmaker, reasoning that doing so ahead of plan confirmation would enable the debtor to make faster distributions to creditors.

  8. March 31, 2025

    Ex-US Trustee Head Appeals Firing, Purdue Case Extended

    The former director of the U.S. Trustee's Office appealed her removal, alleging the government lacked cause and violated due process. Meanwhile, Purdue Pharma secured more time to protect itself and the Sackler family from lawsuits as the company seeks approval for a $7.4 million opioid settlement plan. And FTX told a court it has $11.4 billion ready for creditors but is still reviewing a massive volume of claims before the distribution. 

  9. March 28, 2025

    Purdue Lawsuit Injunction Extended Ahead Of Plan Hearings

    Bankrupt drugmaker Purdue Pharma LP received a further extension of a bar on litigation against the company and its owners in the Sackler family as the debtor pursues a late May approval of a disclosure statement describing a Chapter 11 plan premised on a $7.4 billion settlement of opioid claims.

  10. March 25, 2025

    Purdue Mediators Say US Trustee OK With New Releases

    The mediators guiding plan negotiations among bankrupt drugmaker Purdue Pharma and its various creditor constituencies said in a Tuesday report that the U.S. Trustee's Office has agreed to release language in the debtor's latest plan after fighting an earlier version all the way to the Supreme Court.